Study S003277

A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT07030868
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: TERMINATED
Enrollment: 1
Start: 2025-06-19
Primary completion: 2025-07-29
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Type 2 Diabetes
Interventions: DRUG:LY3549492; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:W8M-MC-GN02; OTHER:W8M-MC-CWMM

Registered primary outcomes

Percent Change From Baseline in Body Weight [Baseline, Week 32]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.